Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead Completes Dosing of First Cohort in Phase IIb HBV Trial


Arrowhead Research announced this week that it has completed enrollment and dosing of the first cohort of patients in an ongoing Phase IIb trial of its hepatitis B drug ARC-520.

The open label, single ascending dose study is set to evaluate ARC-520 at doses of 1.0 mg/kg and 2.0 mg/kg. At each of the dose levels tested, 8 patients will be enrolled with 6 receiving ARC-520 and 2 receiving placebo.

The company reiterated its expectation that all patients will be dosed in the second quarter, with top-line results from the study available in the third quarter.